Rocket Pharmaceuticals, Inc. Announces 2024 Annual Meeting of Stockholders
Ticker: RCKTW · Form: DEF 14A · Filed: Apr 29, 2024 · CIK: 1281895
| Field | Detail |
|---|---|
| Company | Rocket Pharmaceuticals, Inc. (RCKTW) |
| Form Type | DEF 14A |
| Filed Date | Apr 29, 2024 |
| Risk Level | low |
| Pages | 16 |
| Reading Time | 19 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: Proxy Statement, Annual Meeting, Virtual Meeting, Director Election, Notice and Access
TL;DR
<b>Rocket Pharmaceuticals will hold its 2024 Annual Meeting of Stockholders virtually on June 13, 2024, utilizing electronic delivery of proxy materials.</b>
AI Summary
ROCKET PHARMACEUTICALS, INC. (RCKTW) filed a Proxy Statement (DEF 14A) with the SEC on April 29, 2024. The 2024 Annual Meeting of Stockholders for Rocket Pharmaceuticals, Inc. will be held virtually on June 13, 2024, at 9:00 a.m. Eastern Time. The company is utilizing the SEC's 'notice and access' rules, mailing a Notice of Internet Availability of proxy materials instead of paper copies to many stockholders. Stockholders can access the proxy statement and 2023 Annual Report on Form 10-K online, with options to request paper copies. The meeting will include the election of ten directors. The company aims to reduce distribution costs and environmental impact by using electronic delivery of materials.
Why It Matters
For investors and stakeholders tracking ROCKET PHARMACEUTICALS, INC., this filing contains several important signals. The shift to virtual meetings and electronic delivery of materials reflects a trend towards cost-efficiency and environmental consciousness in corporate communications. The election of directors is a critical governance function, allowing shareholders to influence the company's leadership and strategic direction.
Risk Assessment
Risk Level: low — ROCKET PHARMACEUTICALS, INC. shows low risk based on this filing. The filing is a routine proxy statement for an annual meeting, with no immediate financial or operational disclosures that would indicate high risk.
Analyst Insight
Review the nominated directors and any proposals to be voted on at the annual meeting to understand potential shifts in governance or strategy.
Key Numbers
- 10 — Directors to be elected (Annual Meeting Agenda Item)
- 2024 — Annual Meeting Year (Meeting Details)
- 2023 — Annual Report Year (Proxy Materials)
Key Players & Entities
- ROCKET PHARMACEUTICALS, INC. (company) — Registrant
- 0001140361-24-023041 (filing_id) — Accession Number
- 2024-04-29 (date) — Filing Date
- June 13, 2024 (date) — Annual Meeting Date
- 9:00 a.m., Eastern Time (time) — Annual Meeting Time
- www.virtualshareholdermeeting.com/RCKT2024 (url) — Virtual Meeting Link
- 2023 (year) — Annual Report Year
- 10-K (form_type) — Annual Report Form
FAQ
When did ROCKET PHARMACEUTICALS, INC. file this DEF 14A?
ROCKET PHARMACEUTICALS, INC. filed this Proxy Statement (DEF 14A) with the SEC on April 29, 2024.
What is a DEF 14A filing?
A DEF 14A is a definitive proxy statement sent to shareholders before annual meetings, covering executive compensation, board nominations, and shareholder votes. This particular DEF 14A was filed by ROCKET PHARMACEUTICALS, INC. (RCKTW).
Where can I read the original DEF 14A filing from ROCKET PHARMACEUTICALS, INC.?
You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by ROCKET PHARMACEUTICALS, INC..
What are the key takeaways from ROCKET PHARMACEUTICALS, INC.'s DEF 14A?
ROCKET PHARMACEUTICALS, INC. filed this DEF 14A on April 29, 2024. Key takeaways: The 2024 Annual Meeting of Stockholders for Rocket Pharmaceuticals, Inc. will be held virtually on June 13, 2024, at 9:00 a.m. Eastern Time.. The company is utilizing the SEC's 'notice and access' rules, mailing a Notice of Internet Availability of proxy materials instead of paper copies to many stockholders.. Stockholders can access the proxy statement and 2023 Annual Report on Form 10-K online, with options to request paper copies..
Is ROCKET PHARMACEUTICALS, INC. a risky investment based on this filing?
Based on this DEF 14A, ROCKET PHARMACEUTICALS, INC. presents a relatively low-risk profile. The filing is a routine proxy statement for an annual meeting, with no immediate financial or operational disclosures that would indicate high risk.
What should investors do after reading ROCKET PHARMACEUTICALS, INC.'s DEF 14A?
Review the nominated directors and any proposals to be voted on at the annual meeting to understand potential shifts in governance or strategy. The overall sentiment from this filing is neutral.
How does ROCKET PHARMACEUTICALS, INC. compare to its industry peers?
Rocket Pharmaceuticals operates in the pharmaceutical preparations industry, focusing on developing and commercializing therapies.
Are there regulatory concerns for ROCKET PHARMACEUTICALS, INC.?
The filing is made under the Securities Exchange Act of 1934, specifically Schedule 14A, which governs the solicitation of proxies.
Industry Context
Rocket Pharmaceuticals operates in the pharmaceutical preparations industry, focusing on developing and commercializing therapies.
Regulatory Implications
The filing is made under the Securities Exchange Act of 1934, specifically Schedule 14A, which governs the solicitation of proxies.
What Investors Should Do
- Review the list of nominated directors and their qualifications.
- Understand any proposals being presented for shareholder vote.
- Access the 2023 Annual Report on Form 10-K for a comprehensive overview of the company's financial performance and business operations.
Key Dates
- 2024-06-13: 2024 Annual Meeting of Stockholders — Key date for shareholder voting and governance decisions.
- 2024-04-29: Filing Date of Definitive Proxy Statement — Indicates when the official proxy materials were made public.
Year-Over-Year Comparison
This is a Definitive Proxy Statement (DEF 14A) for the 2024 Annual Meeting, indicating a routine annual corporate event.
Filing Stats: 4,820 words · 19 min read · ~16 pages · Grade level 12.3 · Accepted 2024-04-29 16:42:27
Filing Documents
- ny20023925x3_def14a.htm (DEF 14A) — 1219KB
- logo_rocketpharma.jpg (GRAPHIC) — 29KB
- ny20023925x3_pc01.jpg (GRAPHIC) — 580KB
- ny20023925x3_pc02.jpg (GRAPHIC) — 595KB
- ny20023925x3_pvpchart01.jpg (GRAPHIC) — 119KB
- ny20023925x3_pvpchart03.jpg (GRAPHIC) — 115KB
- 0001140361-24-023041.txt ( ) — 5795KB
- rckt-20240613.xsd (EX-101.SCH) — 6KB
- rckt-20240613_def.xml (EX-101.DEF) — 6KB
- rckt-20240613_lab.xml (EX-101.LAB) — 19KB
- rckt-20240613_pre.xml (EX-101.PRE) — 10KB
- ny20023925x3_def14a_htm.xml (XML) — 236KB
EXECUTIVE COMPENSATION
EXECUTIVE COMPENSATION 37 2023 Summary Compensation Table 37 Equity Incentive Awards 40 Executive Agreements; Termination and Change in Control Benefits 40 CEO Pay Ratio 43 Pay Versus Performance 45 DIRECTOR COMPENSATION 49 2023 Director Compensation Table 50 TRANSACTIONS WITH RELATED PERSONS 51 Policies and Procedures for Related Person Transactions 51 Certain Related-Person Transactions 51
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 52 Delinquent Section 16 Reports 54 EQUITY COMPENSATION PLAN INFORMATION 55 STOCKHOLDER PROPOSALS AND NOMINATIONS 56 OTHER MATTERS 56 AVAILABILITY OF CERTAIN DOCUMENTS 56 TABLE OF CONTENTS PROXY STATEMENT FOR THE 2024 ANNUAL MEETING OF STOCKHOLDERS TO BE HELD ON JUNE 13, 2024 The following information is provided to each stockholder in connection with the Annual Meeting of Stockholders (the "Annual Meeting") of Rocket Pharmaceuticals, Inc. ("Rocket" or the "Company") to be held virtually via the Internet at www.virtualshareholdermeeting.com/RCKT2024 on Thursday, June 13, 2024, at 9:00 a.m., Eastern Time. The enclosed proxy is for use at the Annual Meeting and any postponement or adjournment thereof. The Company anticipates that the Notice of Internet Availability in connection with these proxy solicitation materials will first be mailed on or about April 29, 2024 to all stockholders entitled to vote at the Annual Meeting and we will post our proxy materials on the website referenced in the Notice of Internet Availability. As more fully described in the Notice of Internet Availability, all stockholders may choose to access our proxy materials on the website referred to in the Notice of Internet Availability or may request to receive a printed set of our proxy materials. The Company's principal executive offices are located at 9 Cedarbrook Drive, Cranbury, New Jersey 08512, and the Company's website is www.rocketpharma.com . Important Notice Regarding the Availability of Proxy Materials for the Annual Meeting to be Held on June 13, 2024. This Notice of Annual Meeting of Stockholders and Proxy Statement and our 2023 Annual Report on Form 10-K are available at www.proxyvote.com and through our website at the address specified above. 1 TABLE OF CONTENTS GENERAL INFORMATION As used in this proxy statement, the "Company," "Rocket," "we," "us" and "our" refer to Rocket Pharmaceu